Literature DB >> 23129109

Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurement.

Emily B Franzblau1, Rowena C Punzalan, Kenneth D Friedman, Angshumoy Roy, Ozlem Bilen, Veronica H Flood.   

Abstract

We report a patient with dysfibrinogenemia treated with purified fibrinogen concentrate who had discrepant post-treatment laboratory values. The patient had mild bleeding symptoms and was diagnosed with dysfibrinogenemia based on fibrinogen activity of 51 mg/dl and antigen of 240 mg/dl. He was treated for an adenoidectomy with purified fibrinogen concentrate (RiaSTAP®) at a dose of 70 mg/kg. A discrepancy in post-treatment fibrinogen activity was observed between the hospital and reference laboratories. Investigation revealed differences in laboratory assay and calibration methods. Fibrinogen concentrate may be a treatment option for patients with dysfibrinogenemia, but accurate laboratory technique is critical for fibrinogen measurement.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23129109      PMCID: PMC4461026          DOI: 10.1002/pbc.24383

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  11 in total

1.  Nucleotide sequences of the three genes coding for human fibrinogen.

Authors:  D W Chung; J E Harris; E W Davie
Journal:  Adv Exp Med Biol       Date:  1990       Impact factor: 2.622

2.  Incorporation of fibrin molecules containing fibrinopeptide A alters clot ultrastructure and decreases permeability.

Authors:  Veronica H Flood; Chandrasekaran Nagaswami; Irina N Chernysh; Hamid A Al-Mondhiry; John W Weisel; David H Farrell
Journal:  Br J Haematol       Date:  2007-07       Impact factor: 6.998

3.  A database for human fibrinogen variants.

Authors:  M Hanss; F Biot
Journal:  Ann N Y Acad Sci       Date:  2001       Impact factor: 5.691

Review 4.  Fibrinogen replacement therapy for congenital fibrinogen deficiency.

Authors:  L Bornikova; F Peyvandi; G Allen; J Bernstein; M J Manco-Johnson
Journal:  J Thromb Haemost       Date:  2011-09       Impact factor: 5.824

5.  The fibrinogen Aalpha R16C mutation results in fibrinolytic resistance.

Authors:  Veronica H Flood; Hamid A Al-Mondhiry; David H Farrell
Journal:  Br J Haematol       Date:  2006-07       Impact factor: 6.998

Review 6.  Congenital fibrinogen disorders.

Authors:  Philippe de Moerloose; Marguerite Neerman-Arbez
Journal:  Semin Thromb Hemost       Date:  2009-07-13       Impact factor: 4.180

7.  Inherited abnormalities of fibrinogen: 10-year clinical experience of an Italian group.

Authors:  Rosa Santacroce; Filomena Cappucci; Daniela Pisanelli; Fabio Perricone; Maria Luisa Papa; Rita Santoro; Elvira Grandone; Maurizio Margaglione
Journal:  Blood Coagul Fibrinolysis       Date:  2006-06       Impact factor: 1.276

Review 8.  Rare inherited disorders of fibrinogen.

Authors:  S S Acharya; D M Dimichele
Journal:  Haemophilia       Date:  2008-11       Impact factor: 4.287

9.  Pharmacokinetics and safety of fibrinogen concentrate.

Authors:  M J Manco-Johnson; D Dimichele; G Castaman; S Fremann; S Knaub; U Kalina; F Peyvandi; G Piseddu; P Mannucci
Journal:  J Thromb Haemost       Date:  2009-10-05       Impact factor: 5.824

Review 10.  Three-dimensional structural studies on fragments of fibrinogen and fibrin.

Authors:  R F Doolittle; G Spraggon; S J Everse
Journal:  Curr Opin Struct Biol       Date:  1998-12       Impact factor: 6.809

View more
  2 in total

1.  Combined use of Clauss and prothrombin time-derived methods for determining fibrinogen concentrations: Screening for congenital dysfibrinogenemia.

Authors:  Liqun Xiang; Meiling Luo; Jie Yan; Lin Liao; Weijie Zhou; Xuelian Deng; Donghong Deng; Peng Cheng; Faquan Lin
Journal:  J Clin Lab Anal       Date:  2017-09-18       Impact factor: 2.352

2.  Congenital fibrinogen disorders with repeated thrombosis.

Authors:  Xiuli Zhang; Chuang Zhang; Baoheng Wang; Ningheng Chen; Gaihe Sun; Xueli Guo
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.